A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Trial ID or NCT#

NCT01101438

Status

not recruiting iconNOT RECRUITING

Purpose

This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.

Official Title

A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Eligibility Criteria

Ages Eligible for Study: 18 Years to 74 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061